Erik C. Emerson - 16 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: APUS
Reported as of: 16 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2025, 16:56:19 UTC
Prior SEC filing: 08 May 2025
Next SEC filing: 17 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Erik C. Emerson filed Form 4 for Apimeds Pharmaceuticals US, Inc. (APUS) on 20 May 2025.

Key facts

This page summarizes Erik C. Emerson's Form 4 filing for Apimeds Pharmaceuticals US, Inc. (APUS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 May 2025, 16:56.

Change

Previous filing in this sequence was filed on 08 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001710496 Primary reporting owner

Emerson Erik C.

Relationship: Chief Executive Officer, Director
Address: C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 20 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APUS transaction

Common Stock, par value $0.01 per share

Award

Transaction value: $0
Shares: +750,000
Change %
Price: $0.000000
Shares after: 750,000
Date: 16 May 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APUS transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +347,279
Change %
Price: $0.000000
Shares after: 347,279
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 347,279
Exercise price: $1.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Forty percent (40%) of the options vested immediately upon grant, and the remainder will vest in three equal annual installments beginning on 05/16/2026. The reporting person has agreed not to sell any shares underlying the options, even if exercised, for a period of three years from the date of grant.